Truist Securities Lowers Aveanna Healthcare's Price Target to $5.00, Analyst Maintains 'Hold' Rating
ByAinvest
Wednesday, Jul 16, 2025 1:37 pm ET1min read
AVAH--
The new price target of $5.00 is based on the average one-year price target from 8 analysts, which stands at $5.84. The average brokerage recommendation from these analysts is 3.1, indicating a "Hold" status. This suggests a cautious outlook on the stock's future performance.
GuruFocus estimates the GF Value for AVAH to be $2.60, suggesting a potential 34.34% downside from the current price. GF Value is calculated based on historical multiples and future performance estimates, providing a measure of the stock's fair value.
The revised price target and rating reflect Truist Securities' assessment of Aveanna Healthcare's current market position and future prospects. The company operates as a diversified home care platform, providing pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform aims to minimize the overutilization of high-cost care settings.
Institutional investors and hedge funds hold a significant portion of Aveanna Healthcare's stock, with 87.96% of the shares currently owned by these entities. Recent insider transactions have also indicated a decrease in ownership, with major shareholders selling shares in recent months.
The market response to this update has been mixed, with shares of AVAH trading down 2.4% on July 2, 2025, hitting $3.95. The stock's 50-day and 200-day simple moving averages stand at $5.10 and $4.85, respectively. The company's market capitalization is $769.63 million, with a PE ratio of 197.25 and a beta of 1.98.
References:
[1] https://www.marketbeat.com/instant-alerts/truist-financial-has-lowered-expectations-for-aveanna-healthcare-nasdaqavah-stock-price-2025-07-16/
[2] https://www.gurufocus.com/news/2981630/citigroup-c-maintains-buy-rating-as-price-target-raised-by-truist-securities-c-stock-news
C--
Truist Securities has revised its price target for Aveanna Healthcare Holdings (AVAH) to $5.00 from $6.00, a 16.67% decrease. The analyst firm maintains its "Hold" rating. The average one-year price target from 8 analysts is $5.84, with an average brokerage recommendation of 3.1, indicating a "Hold" status. The estimated GF Value for AVAH is $2.60, suggesting a 34.34% downside from the current price.
On July 2, 2025, Truist Securities revised its price target for Aveanna Healthcare Holdings (AVAH) from $6.00 to $5.00, representing a 16.67% decrease. The analyst firm maintained its "Hold" rating on the stock. This adjustment comes amidst ongoing market fluctuations and evolving industry dynamics.The new price target of $5.00 is based on the average one-year price target from 8 analysts, which stands at $5.84. The average brokerage recommendation from these analysts is 3.1, indicating a "Hold" status. This suggests a cautious outlook on the stock's future performance.
GuruFocus estimates the GF Value for AVAH to be $2.60, suggesting a potential 34.34% downside from the current price. GF Value is calculated based on historical multiples and future performance estimates, providing a measure of the stock's fair value.
The revised price target and rating reflect Truist Securities' assessment of Aveanna Healthcare's current market position and future prospects. The company operates as a diversified home care platform, providing pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform aims to minimize the overutilization of high-cost care settings.
Institutional investors and hedge funds hold a significant portion of Aveanna Healthcare's stock, with 87.96% of the shares currently owned by these entities. Recent insider transactions have also indicated a decrease in ownership, with major shareholders selling shares in recent months.
The market response to this update has been mixed, with shares of AVAH trading down 2.4% on July 2, 2025, hitting $3.95. The stock's 50-day and 200-day simple moving averages stand at $5.10 and $4.85, respectively. The company's market capitalization is $769.63 million, with a PE ratio of 197.25 and a beta of 1.98.
References:
[1] https://www.marketbeat.com/instant-alerts/truist-financial-has-lowered-expectations-for-aveanna-healthcare-nasdaqavah-stock-price-2025-07-16/
[2] https://www.gurufocus.com/news/2981630/citigroup-c-maintains-buy-rating-as-price-target-raised-by-truist-securities-c-stock-news

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet